ArticleLiver international : official journal of the International Association for the Study of the Liver2025
The Prognostic Value of the XPC rs2228001 Single Nucleotide Polymorphism in Cholangiocarcinoma.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Inflammation and RNA-Related Polymorphisms in Resected Cholangiocarcinoma: Prognostic Associations in Intrahepatic and Perihilar Tumors.Journal of gastrointestinal cancer · 2026Article
- Prognostic, Predictive, and Clinical Relevance of DNA Damage Repair Alterations in Biliary Tract Cancers.Cancers · 2026Review
- The Prognostic Value of the XPC rs2228001 Single Nucleotide Polymorphism in Cholangiocarcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
BACKGROUND AND
aimsCholangiocarcinoma (CCA) is one of the most prevalent primary liver malignancies with increasing incidence and mortality rates, particularly in Southeast Asia. Surgical resection is a primary therapeutic option offered to patients with localised disease. Unfortunately, early disease recurrence is common and robust tools for tailored patient-centric post-operative management and follow-up schemes are highly desired but currently lacking. To address this unmet clinical need, this study investigated the clinical utility of the single nucleotide polymorphisms (SNPs) in DNA repair genes (ERCC5 rs1047768, APEX1 rs1130409, PARP1 rs1805414, XPC rs2228001 and ERCC5 rs873601) and patient prognosis after curative intent surgery.
methodsA cohort of 229 patients who underwent surgical treatment for intrahepatic (iCCA) and perihilar (pCCA) cholangiocarcinoma was examined. Kaplan-Meier and multivariable Cox regression analyses were used to assess the impact of these SNPs on recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS).
resultsWithin comprehensive multivariable analyses, the TT genotype of XPC rs2228001 was significantly associated with prolonged RFS (GG/GT = 1, HR = 0.50, p = 0.027), CSS (HR = 0.42, p = 0.018) and OS (HR = 0.31; p = 0.031) in iCCA. Similarly, in pCCA, the TT genotype of XPC rs2228001 was an independent prognostic factor for prolonged CSS (GG/GT = 1, HR = 0.48, p = 0.041).
conclusionsThese findings suggest that SNPs in DNA repair genes, particularly XPC rs2228001, play a crucial role in modulating the prognosis of CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.